We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Asthma Medicine Hailed as Effective Treatment for COVID-19

By HospiMedica International staff writers
Posted on 13 Jul 2020
Image: Asthma Medicine Hailed as Effective Treatment for COVID-19 (Photo courtesy of Queensland University of Technology).
Image: Asthma Medicine Hailed as Effective Treatment for COVID-19 (Photo courtesy of Queensland University of Technology).
Budesonide, a medicine used to help prevent the symptoms of asthma, is being touted as the “silver bullet” for COVID-19.

Budesonide, a corticosteroid or steroid, reduces the severity of asthma attack by preventing inflammation in the lungs and can be inhaled directly to the lungs using a nebulizer. Daily use of inhaled budesonide reduces the number and severity of asthma attacks, although it cannot provide relief from an asthma attack that is already underway. Dr. Richard Bartlett, a US doctor, believes that budesonide, otherwise known as the brand name Pulmicor, can successfully treat the coronavirus. Dr. Bartlett claims to have used inhaled, generic budesonide to cure several COVID-19 patients who have vouched for his treatment.

Now, researchers from the Queensland University of Technology (QUT Brisbane, Australia) and the University of Oxford (Oxford, UK) are collaborating to test common asthma inhalers as a treatment for COVID-19 infection. The STOIC (STerOids In COVID-19) trial will look at whether asthma inhalers given to people with early stage COVID-19 can reduce progression of respiratory illness and cut emergency department presentations and hospital admissions. Some patients will be given budesonide, while others will be given a placebo. Recruitment for the trial has begun and the researchers will be coordinating trial data analysis, modelling of pathological mechanisms and building COVID-19 maths models to explain and use the clinical trial data to optimize patient treatment. Mathematical modelling by the STOIC study team suggests that the earlier the inhaled steroid treatment is applied, the more people can be stopped from becoming sick.

“Ideally it may be that the corticosteroid therapy would be given to anyone with a new, dry cough, and while they are awaiting their COVID test results,” said associate Professor Nicolau, from the QUT Science and Engineering Faculty School of Mathematical Sciences.

Related Links:
Queensland University of Technology
University of Oxford


Gold Member
12-Channel ECG
CM1200B
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Patient Preoperative Skin Preparation
BD ChloraPrep
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter

Channels

Critical Care

view channel
Image: The device is worn on a finger and measures blood pressure without an arm‑compressing cuff (Photo courtesy of Sky Labs)

Ring-Type Cuffless Monitor Becomes First Added to Official Hypertension Guidelines

Detecting nocturnal and morning hypertension often requires out-of-office assessment, but conventional cuff-type monitors can disrupt sleep. New national guidance in South Korea expands 24-hour monitoring... Read more